enoximone


Also found in: Wikipedia.

enoximone

 [en-ok´sĭ-mōn]
a vasodilator similar to inamrinone; used as a cardiotonic in the short-term management of congestive heart failure, administered intravenously.

enoximone

/enox·i·mone/ (en-ok´sĭ-mōn) a phosphodiesterase inhibitor similar to inamrinone; used as a cardiotonic in the short-term management of congestive heart failure, administered intravenously.

enoximone

[enok′sĭmōn]
a vasodilator similar to inamrinone, used as a cardiotonic in the short-term management of congestive heart failure. It is administered intravenously.

enoximone

A PHOSPHODIESTERASE INHIBITOR drug used to improve the heart's action in HEART FAILURE. A brand name is Perfan.
References in periodicals archive ?
Levosimendan is superior to enoximone in refractory cardiogenico shock complicating acute myocardial infarction.
Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double-blind trial.
Anaesthetists commonly administer [beta]-adrenergic agonists (dobutamine, dopamine or adrenaline) as first-line inotropic therapy, with secondary addition of milrinone or enoximone before the institution of mechanical support.
TORONTO -- Low doses of oral enoximone, an investigational positive inotrope, may help safely wean advanced heart failure patients from intravenous inotropes, according to data from a phase III randomized trial.
Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared to placebo.
The decrease in expenses from 2005 was primarily due to the discontinuation of the development of enoximone, which was partially offset by growth in expenses related to darusentan and increased stock-based compensation expense.
Beta blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Weaning from CPB was achieved using atrial pacing, IABP, enoximone and noradrenaline.
The decrease in expenses for 2005 was primarily due to the discontinuation of the development of enoximone capsules, which was largely offset by growth in expenses related to ambrisentan.